bipolar II disorder
disease diseaseOn this page
Summary
bipolar II disorder (MONDO:0000693) is a disease and 44 clinical trials. Top therapeutic interventions include quetiapine, ketamine, and naltrexone. A subtype of bipolar disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 44
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | bipolar II disorder |
| Mondo ID | MONDO:0000693 |
| DOID | DOID:0060166 |
| ICD-10-CM | F31.81 |
| SNOMED CT | 83225003 |
| UMLS | C0236788 |
| MedGen | 536634 |
| Is cancer (heuristic) | no |
Also known as: bipolar II disorder
Disease family
This is a subtype of bipolar disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › mood disorder › bipolar disorder › bipolar II disorder
Related subtypes (11): bipolar I disorder, major affective disorder 1, major affective disorder 3, major affective disorder 4, major affective disorder 5, major affective disorder 6, major affective disorder 8, major affective disorder 7, major affective disorder 9, manic bipolar affective disorder, bipolar depression
Subtypes (1): major affective disorder 2
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 44.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 17 |
| PHASE2 | 13 |
| PHASE4 | 6 |
| PHASE3 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06184581 | PHASE4 | RECRUITING | Lithium Versus Lamotrigine in Bipolar Disorder, Type II |
| NCT07213466 | PHASE4 | RECRUITING | Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder |
| NCT00186043 | PHASE4 | COMPLETED | Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II |
| NCT00237666 | PHASE4 | COMPLETED | Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression |
| NCT01588457 | PHASE4 | COMPLETED | Sequential Multiple Assignment Treatment for Bipolar Disorder |
| NCT03156504 | PHASE4 | COMPLETED | The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. |
| NCT07172516 | PHASE3 | RECRUITING | A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
| NCT07217860 | PHASE3 | ENROLLING_BY_INVITATION | An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) |
| NCT00411463 | PHASE2/PHASE3 | COMPLETED | Psychotherapy for Bipolar II Depression, Pilot Study, Phase II |
| NCT00761761 | PHASE3 | COMPLETED | Sensoril(Ashwaganhda)for Bipolar Disorder |
| NCT04035798 | PHASE2/PHASE3 | UNKNOWN | add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients |
| NCT05658510 | PHASE3 | COMPLETED | Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III) |
| NCT05064319 | PHASE2 | RECRUITING | Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders |
| NCT05065294 | PHASE2 | ACTIVE_NOT_RECRUITING | Psilocybin Therapy for Depression in Bipolar II Disorder |
| NCT06696755 | PHASE2 | RECRUITING | A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder |
| NCT06706232 | PHASE2 | RECRUITING | Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality |
| NCT01731119 | PHASE2 | COMPLETED | Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents |
| NCT03334721 | PHASE2 | COMPLETED | Gabapentin for Bipolar & Cannabis Use Disorders |
| NCT03822416 | PHASE2 | COMPLETED | Treating Smokers With Mental Illness |
| NCT05004896 | PHASE2 | COMPLETED | Ketamine for Treatment-Resistant Bipolar Disorder |
| NCT05339074 | PHASE2 | COMPLETED | Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression |
| NCT05340504 | PHASE2 | COMPLETED | Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder |
| NCT05839509 | PHASE2 | TERMINATED | Phase 2 Clinical Trial of GH001 in Bipolar II Disorder |
| NCT06605599 | PHASE2 | COMPLETED | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder |
| NCT07116694 | PHASE2 | COMPLETED | Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder |
| NCT03810703 | PHASE1 | COMPLETED | Differential Responses to Drugs and Sweet Tastes |
| NCT02593643 | EARLY_PHASE1 | COMPLETED | Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. |
| NCT03484494 | Not specified | ACTIVE_NOT_RECRUITING | Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression |
| NCT05427123 | Not specified | RECRUITING | Children’s Bipolar Network Treatment Trial I |
| NCT06560957 | Not specified | RECRUITING | SYNCED - SYNChronized Eating in Bipolar Depression Study |
| NCT06804525 | Not specified | RECRUITING | LHC-CIDI-5 in Hong Kong |
| NCT07127913 | Not specified | RECRUITING | Closed-Loop Deep Brain Stimulation for Treatment-Resistant Bipolar Depression |
| NCT01075295 | Not specified | COMPLETED | Prevention of Weight Gain in Early Psychoses |
| NCT02491307 | Not specified | TERMINATED | Ginger.io Behavioral Health Study |
| NCT03603561 | Not specified | UNKNOWN | Continuous Theta Burst Stimulation as an add-on Treatment for Bipolar Depression |
| NCT03641300 | Not specified | COMPLETED | Efficacy of Convulsive Therapies for Bipolar Depression |
| NCT04211428 | Not specified | WITHDRAWN | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Bipolar Disorder |
| NCT04561622 | Not specified | UNKNOWN | Emotional Proactive Processing in Bipolar Disorder |
| NCT05249309 | Not specified | UNKNOWN | Naturalistic Study of Ketamine in the Treatment of Depression |
| NCT05340686 | Not specified | SUSPENDED | Braining- Aerobic Physical Activity as Add on Treatment in Bipolar Depression |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| QUETIAPINE | 4 | 6 |
| KETAMINE | 4 | 3 |
| NALTREXONE | 4 | 3 |
| ZIPRASIDONE | 4 | 3 |
| LAMOTRIGINE | 4 | 2 |
| DIVALPROEX SODIUM | 4 | 1 |
| LITHIUM CARBONATE | 4 | 1 |
| MIDAZOLAM | 4 | 1 |
| SEMAGLUTIDE | 4 | 1 |
| AZETUKALNER | 3 | 2 |
| PSILOCYBIN | 3 | 2 |
| LITHIUM | 3 | 1 |
| MEBUFOTENIN | 2 | 2 |
| ICALCAPRANT | 2 | 1 |
| CHEMBL4547032 | 0 | 2 |
| CHEMBL4556788 | 0 | 1 |
| CHEMBL4752331 | 0 | 1 |
| CHEMBL6147864 | 0 | 1 |
| LITHIUM ION | 0 | 1 |